Previous 10 | Next 10 |
home / stock / nvs / nvs articles
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhib...
Novartis AG (NYSE: NVS) announced topline results from the six-month, double-blind period of the Phase 3 APPEAR-C3G study of iptacop...
The FDA approved Novartis AG's (NYSE: NVS) Fabhalta (iptacopan) as the first oral monotherapy for adult patients with paroxysmal...
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovas...
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patient...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multipl...
Stocks enjoyed a positive midday trading session in New York, with all major indices in the green. Additionally, nine out of 11 S&P 500 sectors...
Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day l...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 09:38:21 ET The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market’s performance is influenced by economic conditions, co...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...